Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi

This study has been completed.

First Received: March 16, 2009 No Changes Posted

Sponsored by:	Ruhr University of Bochum
Information provided by:	Ruhr University of Bochum
ClinicalTrials.gov Identifier:	NCT00862914

Purpose

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the researchers investigate the immunohistochemical distribution of Dicer in benign and dysplastic melanocytic naevi as well as in cutaneous malignant melanoma compared to intraindividual healthy control.

Condition
Naevi Malignant Melanoma

Study Type:	Observational
Study Design:	Case Control, Prospective

Resource links provided by NLM:

MedlinePlus related topics: Melanoma Moles

U.S. FDA Resources

Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Paraffin embedded melanocytic skin lesion

Enrollment:	30
Study Start Date:	July 2008
Study Completion Date:	March 2009
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts
1 benign melanocytic naevi
2 dysplastic melanocytic naevi
3 cutaneous malignant melanoma

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

dermatologic primary care clinic

Criteria

Inclusion Criteria:

Patients with benign melanocytic naevi, dysplastic melanocytic naevi and cutaneous malignant melanoma.

Exclusion Criteria:

Patients under 18 years of age
Patients with other forms of cancer in previous medical history
Pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00862914

Locations

Germany, NRW
Department of Dermatology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791

Sponsors and Collaborators

Ruhr University of Bochum

Investigators

Principal Investigator:	Prof. Dr. Peter Altmeyer	Department of Dermatology and Allergology, Ruhr-University Bochum
Study Director:	PD Dr. Falk G. Bechara	Department of Dermatology and Allergology, Ruhr-University Bochum

More Information

No publications provided

Responsible Party:	Department of Dermatology and Allergology, Ruhr-University Bochum ( Dr. Michael Sand, PD Dr. Falk-Georges Bechara )
Study ID Numbers:	006
Study First Received:	March 16, 2009
Last Updated:	March 16, 2009
ClinicalTrials.gov Identifier:	NCT00862914 History of Changes
Health Authority:	Germany: Ethics Commission

Keywords provided by Ruhr University of Bochum:

Skin
MicroRNA
miRNA
Dicer
Malignant Melanoma

Study placed in the following topic categories:

Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Nevus, Pigmented
Neuroepithelioma

Nevus
Melanoma, Familial
Neuroendocrine Tumors
Melanoma

Additional relevant MeSH terms:

Neuroectodermal Tumors
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue

Nevi and Melanomas
Nevus
Neuroendocrine Tumors
Melanoma

ClinicalTrials.gov processed this record on September 11, 2009